PhillyTablet Inquirer Daily News
philly.com
email
font size
comments
0
options
 
Tuesday, December 2, 2008

Teva Pharmaceutical Industries Ltd., Israel's most valuable company, whose U.S. operations are based in Chester County, "turned itself into the world's biggest maker of generic medicines through a high-risk strategy of flouting drug patents," writes Bloomberg News.

Targets include AstraZeneca's Pulmicort asthma medicine, Sanofi-Aventis's allergy drugs Allegra-D and Nasacort, and, possibly soon, Eli Lilly's Evista osteoperosis treatment. "Teva... risks paying billions of dollars in legal damages by taking a calculated legal gamble: It begins selling copies while patents on a drug are still being disputed in court... The company has pulled off the maneuver 13 times since 2004, helping double annual revenue to $9.41 billion. The strategy gets cheaper, copycat drugs to patients quicker as governments and employers are demanding relief from record health-care costs."

Story at

http://www.bloomberg.com/apps/news?pid=20601109&sid=aS52SijhbcTQ&refer=exclusive

Posted by Joseph N. DiStefano @ 6:51 AM  Permalink | Post a comment
Comments   


0 comments
About Joseph N. DiStefano
Joseph N. DiStefano writes this blog to feed his PhillyDeals column in the Philadelphia Inquirer. Joe has been a member of Bloomberg LP’s New York Finance Team, wrote the book “Comcasted,” taught writing at St. Joseph’s University, and studied economics and history at Penn. Reach Joe at 215-854-5194 and JoeD@phillynews.com